Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy
Y Yan, X Feng, C Li, T Lerut, H Li - Chinese Medical Journal, 2022 - mednexus.org
Esophageal cancer (EC) has a high incidence and poor prognosis. The two major
histological types, squamous cell carcinoma and adenocarcinoma, differ in their …
histological types, squamous cell carcinoma and adenocarcinoma, differ in their …
[HTML][HTML] Systemic treatments for resectable carcinoma of the esophagus
W Leowattana, P Leowattana… - World Journal of …, 2023 - ncbi.nlm.nih.gov
One of the most prevalent malignancies in the world is esophageal cancer (EC). The 5-year
survival rate of EC remains pitiful despite treatment advancements. Neoadjuvant …
survival rate of EC remains pitiful despite treatment advancements. Neoadjuvant …
A novel disulfidptosis-related immune checkpoint genes signature: forecasting the prognosis of hepatocellular carcinoma
Y Chen, W Xue, Y Zhang, Y Gao, Y Wang - Journal of Cancer Research …, 2023 - Springer
Background HCC is an extremely malignant tumor with a very poor prognosis. In 2023, a
brand-new kind of cell death known as disulfidptosis was identified. Although, the prognosis …
brand-new kind of cell death known as disulfidptosis was identified. Although, the prognosis …
[HTML][HTML] IFNγ-Induced Bcl3, PD-L1 and IL-8 Signaling in Ovarian Cancer: Mechanisms and Clinical Significance
SU Reddy, FZ Sadia, A Vancura, I Vancurova - Cancers, 2024 - mdpi.com
Simple Summary IFNγ is a multifunctional cytokine produced not only by activated
lymphocytes but also in response to cancer immunotherapies; it has both antitumor and …
lymphocytes but also in response to cancer immunotherapies; it has both antitumor and …
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
X Ren, L Wang, L Liu, J Liu - Frontiers in Immunology, 2024 - frontiersin.org
Immunotherapy has been developed, which harnesses and enhances the innate powers of
the immune system to fight disease, particularly cancer. PD-1 (programmed death-1) and PD …
the immune system to fight disease, particularly cancer. PD-1 (programmed death-1) and PD …
[HTML][HTML] PD-L1 の細胞内機能と発現制御機構
仁平(平)直江 - Journal of Japanese Biochemical Society, 2022 - seikagaku.jbsoc.or.jp
免疫チェックポイント分子 PD-L1 は多くのがん細胞で高発現がみられ, 細胞膜上にて T
細胞やマクロファージに発現する PD-1 に対するリガンドとして作用し, これらの免疫細胞の不活性 …
細胞やマクロファージに発現する PD-1 に対するリガンドとして作用し, これらの免疫細胞の不活性 …